Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
$47.78+0.63 (+1.34%)
Close on Nov 13, 2026Market cap $6.75BP/E –Yield –
Arrowhead Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Arrowhead Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -156.9%. For fiscal 2026 it was -156.9%, against 11.9% the year before. The highest annual figure on record is 36.3% in fiscal 2019.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Sep 30, 2026 | -156.9% | −168.7 |
| FY2025 | Sep 30, 2025 | 11.9% | +16938.9 |
| FY2024 | Sep 30, 2024 | -16927.1% | −16841.9 |
| FY2023 | Sep 30, 2023 | -85.2% | −11.8 |
| FY2022 | Sep 30, 2022 | -73.4% | +34.4 |
| FY2021 | Sep 30, 2021 | -107.8% | −1.9 |
| FY2020 | Sep 30, 2020 | -105.9% | −142.1 |
| FY2019 | Sep 30, 2019 | 36.3% | +382.8 |
| FY2018 | Sep 30, 2018 | -346.5% | −228.7 |
| FY2017 | Sep 30, 2017 | -117.8% | +51509.3 |
| FY2016 | Sep 30, 2016 | -51627.1% | −26503.0 |
| FY2015 | Sep 30, 2015 | -25124.1% | +5319.5 |
| FY2014 | Sep 30, 2014 | -30443.6% | −21972.3 |
| FY2013 | Sep 30, 2013 | -8471.3% | +5887.3 |
| FY2012 | Sep 30, 2012 | -14358.6% | −11039.1 |
| FY2011 | Sep 30, 2011 | -3319.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ3 2026 | Sep 30, 2026 | -1155.3% | −1172.5 |
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -226.0% | +370.2 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -191.6% | −261.8 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | 15.5% | +6471.9 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | 17.2% | +3862.5 |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -596.2% | +76.8 |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | 70.2% | +719.2 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -6456.5% | −6489.4 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -3845.3% | −3777.9 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -673.0% | −407.5 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -649.0% | −424.0 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | 32.9% | +5.6 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -67.4% | +163.4 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -265.5% | −96.0 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -224.9% | −155.5 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | 27.4% | +113.4 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -230.8% | −117.9 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -169.5% | +487.1 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -69.4% | −11.2 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -86.0% | +8.5 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -112.9% | −96.4 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -656.6% | −678.9 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -58.2% | −101.8 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -94.5% | −140.2 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -16.5% | −48.1 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | 22.3% | +121.5 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | 43.6% | +2232.2 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | 45.7% | +2358.2 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | 31.6% | +425.1 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -99.2% | +18.4 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -2188.7% | −2127.5 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -2312.5% | −2244.3 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -393.6% | −52.2 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -117.6% | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -61.2% | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -68.2% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -341.4% | – |
See a number that looks wrong?